Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology;Toxicité dermatologique des nouvelles thérapies ciblées anticancéreuses utilisées en oncodermatologie

Annales de Chirurgie Plastique Esthetique

Volumn 57, Issue 2, 2012, Pages 106-113

  Sibaud, V ^a   Delord, J P ^a   Chevreau, C ^a   Gangloff, D ^a   Garrido Stowhas, I ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Ipilimumab; Selumetinib; Skin toxicity; Vemurafenib; Vismodegib

Indexed keywords

EID: 84859831660     PISSN: 02941260     EISSN: 1768319X     Source Type: Journal    
DOI: 10.1016/j.anplas.2012.02.002     Document Type: Short Survey

References (53)

1. Lacouture M.E., Anadkar M.J., Bensadoun R.J., Bryce J., Chan A., Epstein J.B., et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 2011, 19:1079-1095.
2. Maubec E., Petrow P., Scheer-Senyarich I., Duvillard P., Lacroix L., Gelly J., et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011, 29:3419-3426.
3. Caron J., Dereure O., Kerob D., Lebbe C., Guillot B. Metastatic basal cell carcinoma: report of two cases treated with cetuximab. Br J Dermatol 2009, 161:702-703.
4. Cowen E.W. Epidermal growth factor receptor inhibitors: a new era of drug reactions in a new era of cancer therapy. J Am Acad Dermatol 2007, 56:514-517.
5. Robert C., Soria J.C., Spatz A., Le Cesne A., Malka D., Pautier P., et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005, 6:491-500.
6. Deslandres M., Sibaud V., Chevreau C., Delord J.P. Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors. Ann Dermatol Venereol 2008, 1:16-24.
7. Hu J.C., Sadeghi P., Pinter-Brown L.C., Yashar S., Chiu M.W. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 2007, 56:317-326.
8. Jatoi A., Nguyen P.L. Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy. Oncologist 2008, 13:1201-1204.
9. Lacouture M.E., Cotliar J., Mitchell E.P. Clinical management of EGFRI dermatologic toxicities: US perspective. Oncology 2007, 21:17-21.
10. Eaby B., Culkin A., Lacouture M.E. An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors. Clin J Oncol Nurs 2008, 12:283-290.
11. Thatcher N., Nicolson M., Groves R.W., Steele J., Eaby B., Dunlop J., et al. Expert consensus on the management of erlotinib-associated cutaneous toxicity in the UK. Oncologist 2009, 14:840-847.
12. Fox L.P. Nail toxicity associated with epidermal growth factor receptor inhibitor therapy. J Am Acad Dermatol 2007, 56:460-465.
13. Sibaud V., Dalenc F., mourey L., Chevreau C. Paronychia and pyogenic granuloma induced by new anticancer mTOR inhibitors. Acta Dermatol Venereol 2011, 91:584-585.
14. Osio A., Mateus C., Soria J.C., Massard C., Malka D., Boige V., et al. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br J Dermatol 2009, 161:515-521.
15. Von Hoff D., LoRusso P.M., Rudin C.M., Reddy J.C., Yauch R.L., Tibes R., et al. Inhibition of the hedgehog pathway in advanced basal cell carcinoma. New Engl J Med 2009, 361:1164-1172.
16. De Smaele E., Ferretti E., Gulino A. Vismodegib, a small-molecule inhibitor of the Hedgehog pathway for the treatment of advanced cancers. Curr Opin Invest Drugs 2010, 11:707-718.
17. LoRusso P.M., Jimeno A., Dy G., Adjei A., Berlin J., Leichman L., et al. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumours. Clin Cancer Res 2011, 17:5774-5782.
18. LoRusso P.M., Rudin C.M., Reddy J.C., Tibes R., Weiss G.J., et al. Phase I trial of Hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumours. Clin Cancer Res 2011, 17:2502-2511.
19. Eggermont A.M., Robert C. New drugs in melanoma: it's a whole new world. Eur J Cancer 2011, 47:2150-2157.
20. Robert C., Arnault J.P., Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol 2011, 23:177-182.
21. Smalley K.S.M. PLX-4032, a small-molecule B-raf inhibitor for the potential treatment of malignant melanoma. Curr Opin Invest Drugs 2010, 11:699-706.
22. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2515.
23. Ribas A., Kim K.B., Schuchter L.M., et al. BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. J Clin Oncol 2011, 29. [suppl.; abstr. 8509].
24. Sibaud V., Garrido-Stowhas I., Cottura E., Chevreau C. Dermatologic side effects induced by new angiogenesis inhibitors. Bull Cancer 2011, 98:1221-1229.
25. Sibaud V., Chevreau C. Manifestations dermatologiques des thérapies ciblées antiangiogéniques. Manifestations cutanées des thérapies ciblées anticancéreuses : une nouvelle dermatologie 2010, 41-59. Privat, Toulouse. V. Sibaud, C. Robert (Eds.).
26. Robert C., Mateus C., Spatz A., Wechsler J., Escudier B. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 2009, 60:299-305.
27. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819.
28. Arnault J.P., Mateus C., Escudier B., Tomasic G., Wechsler J., Hollville E., et al. Skin tumors induced by sorafenib; paradoxical RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53 and TGFBR1. Clin Cancer Res 2012, 18:263-272.
29. Kong H.H., Turner M.L. Array of cutaneous adverse effects associated with sorafenib. J Am Acad Dermatol 2009, 61:360-361.
30. Kong H.H., Sibaud V., Chanco Turner M.L., Fojo T., Hornyak T.J., Chevreau C. Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol 2008, 144:820-822.
31. Bennani-Lahlou M., Mateus C., Escudier B., Massard C., Soria J.C., Spatz A. Eruptive nevi associated with sorafenib treatment. Ann Dermatol Venereol 2008, 135:672-674.
32. Sibaud V. Toxicité cutanée induite par les thérapies ciblées anti-angiogéniques. Oncologie 2009, 11:291-297.
33. Boasberg P., Hamid O., O'Day S. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockage. Semin Oncol 2010, 37:440-449.
34. Robert C., Ghiringhelli F. What is the role of cytotoxic T lymphocyte-associated antigen 4 blockage in patients with metastatic melanoma?. Oncologist 2009, 14:848-861.
35. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
36. Robert C., Thomas L., Bondakero I., O'Day S., Weber J., Garbe C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526.
37. Weber J., Thompson J.A., Hamid O., Minor D., Amin A., Ron I., et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009, 15:5591-5598.
38. Di Giacomo A.M., Biagioli M., Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010, 37:499-507.
39. Robert C. Manifestations dermatologiques des anticorps anti-CTLA-4. Manifestations cutanées des thérapies ciblées anticancéreuses : une nouvelle dermatologie 2010, 89-94. Privat, Toulouse. V. Sibaud, C. Robert (Eds.).
40. Ribas A., Camacho L.H., Lopez-Berestein G., Pavlov D., Bulanhagui C.A., Millham R., et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005, 23:8968-8977.
41. Bekaii-Saab T., Phelps M.A., Li X., Saji M., Goff L., Sae Wook Kauh J., et al. Multi-institutional phase II of selumetinib in patients with metastatic biliary cancers. J Clin Oncol 2011, 29:2357-2363.
42. Schad K., Baumann Conzett K., Zipser M.C., Enderlin V., Kalmarashev J., French L.E., et al. Mitogen-activated protein/extracellular signal-regulated kinase inhibition results in biphasic alteration of epidermal homeostasis with kerantinocytic apoptosis and pigmentation disorders. Clin Cancer Res 2010, 16:1058-1064.
43. Adjei A.A., Cohen R.B., Francklin W., Morris C., Wilson D., Molina J.R., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD 6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008, 26:2139-2146.
44. Desar I.M., Bovenschen H.J., Timmer-Bonte A.J., Cantarini M.V., Van Der Graaf W.T., Van Rossum M.M., et al. Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142883) in patients with solid tumours. Acta Oncol 2010, 49:110-113.
45. Balagula Y., Huston K.B., Busam K.J., Lacouture M.E., Chapman P.B., Myskowski P.L. Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest New Drugs 2011, 29:1114-1121.
46. Querfeld C., Duffy K., Magel G., Oble D., Cohen E.E.W., Shea C.R. Disseminated follicular eruption during therapy with the MEK inhibitor AZD6244. J Am Acad Dermatol 2011, 64:e17-e19.
47. Thomas M., Robert C. Dermatologic manifestations of MEK inhibitors. Cutaneous side effects induced by targeted anticancer therapies: a new dermatology 2010, 71-82. Privat, Toulouse. V. Sibaud, C. Robert (Eds.).
48. Scheinfeld N. Inmatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol 2006, 5:228-231.
49. Valeyrie-Allanore L. Manifestations dermatologiques des inhibiteurs de BCR-ABL, c-KIT et PDGFR. Manifestations cutanées des thérapies ciblées anticancéreuses : une nouvelle dermatologie 2010, 61-70. Privat, Toulouse. V. Sibaud, C. Robert (Eds.).
50. Amitay-Laish I., Stemmer S.M., Lacouture M.E. Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dastinib. Dermatol Ther 2011, 24:386-395.
51. Valeyrie L., Bastuji-Garin S., Revuz J., Bachot N., Wechsler J., Berthaud P., et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukamias: a prospective study of 54 patients. J Am Acad Dermatol 2003, 48:201-206.
52. Heidary N., Naik H., Burgin S. Chemotherapeutic agents and the skin: an update. J Am Acad Dermatol 2008, 58:545-570.
53. Arora B., Kumar L., Sharma A., Wadhwa J., Kochupillai V. Pigmentary changes in chronic myeloid leukaemia patients treated with imatinib mesylate. Ann Oncol 2004, 15:358-359.